The AAFP concludes that evidence is insufficient to recommend for or against routine screening for elevated blood lead levels in asymptomatic children aged 1 to 5 years who are at increased risk.
Clinical Considerations: www.ahrq.gov/clinic/uspstf06/lead/leadrs.htm#Clinical
K-O: Recommendations for Clinical Preventive Services
Lead Poisoning
Lead Poisoning
The AAFP recommends against routine screening for elevated blood levels in asymptomatic pregnant women.
Clinical Considerations: www.ahrq.gov/clinic/uspstf06/lead/leadrs.htm#Clinical
Clinical Considerations: www.ahrq.gov/clinic/uspstf06/lead/leadrs.htm#Clinical
Lead Poisoning
The AAFP recommends against routine screening for elevated blood levels in asymptomatic children aged 1 to 5 years who are at average risk.
Clinical Considerations: www.ahrq.gov/clinic/uspstf06/lead/leadrs.htm#Clinical
Clinical Considerations: www.ahrq.gov/clinic/uspstf06/lead/leadrs.htm#Clinical
Lipid Disorders
The AAFP strongly recommends screening for lipid disorders with either a fasting lipid profile or nonfasting total cholesterol and HDL cholesterol in males age 35 and older, and females age 45 and older.
Clinical Considerations: www.ahrq.gov/clinic/ajpmsuppl/lipidrr.htm#section2
Clinical Considerations: www.ahrq.gov/clinic/ajpmsuppl/lipidrr.htm#section2
Lipid Disorders
The AAFP concludes that the evidence is insufficient to recommend for or against routine screening for lipid disorders in infants, children, adolescents, or young adults (up to age 20).
Clinical Considerations: www.ahrq.gov/clinic/uspstf07/chlipid/chlipidrs.htm#clinical
Clinical Considerations: www.ahrq.gov/clinic/uspstf07/chlipid/chlipidrs.htm#clinical
Lung Cancer
The AAFP recommends against the use of chest X-ray and/or sputum cytology in asymptomatic persons for lung cancer screening.
Clinical Consideration: http://www.ahrq.gov/clinic/uspstf/uspslung.htm
Clinical Consideration: http://www.ahrq.gov/clinic/uspstf/uspslung.htm
Measles
The AAFP strongly recommends immunizing all children for measles using AAFP recommendations unless contraindicated.
Recommended Childhood and Adolescent Immunization Schedule
Recommended Childhood and Adolescent Immunization Schedule
Measles, Mumps, Rubella
The AAFP strongly recommends immunizing all persons born after 1956 who lack evidence of immunity to measles (receipt of live vaccine on or after the first birthday, laboratory evidence of immunity, or a history of physician-diagnosed measles) with a single dose for measles, mumps, rubella.
Recommended Adult Immunization Schedule
Recommended Adult Immunization Schedule
Measles, Mumps, Rubella
The AAFP strongly recommends immunizing adolescents and young
adults in settings where such individuals congregate (e.g., high schools, technical schools, and colleges), if they have not previously received a second dose for measles, mumps, rubella. Give second dose at least 1 month after first dose.
Recommended Adult Immunization Schedule
adults in settings where such individuals congregate (e.g., high schools, technical schools, and colleges), if they have not previously received a second dose for measles, mumps, rubella. Give second dose at least 1 month after first dose.
Recommended Adult Immunization Schedule
Mumps
The AAFP strongly recommends immunizing all children for mumps using AAFP recommendations unless contraindicated.
Recommended Childhood and Adolescent Immunization Schedule
Recommended Childhood and Adolescent Immunization Schedule
Meningococcus, Conjugate Vaccine (Adolescents)
The AAFP recommends routine vaccination of adolescents: young adolescents at a pre-adolescent visit (11-12 years old); adolescents at high school entry (15 years old) for those who have not previously received MCV4; and other adolescents who wish to decrease their risk of meningococcal disease.
AAFP Clinical Recommendations for Immunizations
AAFP Clinical Recommendations for Immunizations
Meningococcus, Conjugate Vaccine
The AAFP recommends for routine vaccination of other populations at increased risk of meningococcal disease: college freshman living in dormitories; microbiologists who are routinely exposed to isolates of N. meningitides; military recruits; persons who travel to or reside in countries in which N. meningitides is hyperendemic or epidemic, particularly if contact with local population will be prolonged; persons who have terminal complement component deficiencies, and those who have anatomic or functional asplenia; and other adolescents, college students and HIV patients who wish to decrease their risk of meningococcal disease.
AAFP Clinical Recommendations for Immunizations
AAFP Clinical Recommendations for Immunizations
Neural tube defects
The AAFP strongly recommends prescribing 0.4-0.8 mg/day of folic acid supplementation from at least 1 month prior to conception through the first trimester of pregnancy to women planning to become pregnant who have not had a previous pregnancy affected by a neural tube defect.
Clinical Consideration: www.ahrq.gov/clinic/uspstf/uspsneur.htm
Clinical Consideration: www.ahrq.gov/clinic/uspstf/uspsneur.htm
Neural tube defects
The AAFP recommends prescribing 0.4 mg folate supplementation to women not planning a pregnancy but of childbearing potential who have not previously had a baby with a neural tube defect.
Clinical Consideration: www.ahrq.gov/clinic/uspstf/uspsneur.htm
Clinical Consideration: www.ahrq.gov/clinic/uspstf/uspsneur.htm
Neural tube defects
The AAFP strongly recommends prescribing 4 mg/day of folic acid supplementation from 1-3 months prior to conception through the first trimester of pregnancy to women who are planning a pregnancy and had a previous pregnancy affected by a neural tube defect.
Clinical Consideration: www.ahrq.gov/clinic/uspstf/uspsneur.htm
Clinical Consideration: www.ahrq.gov/clinic/uspstf/uspsneur.htm
Obesity
The AAFP recommends that family physicians screen all adult patients for obesity and offer intensive counseling and behavioral interventions to promote sustained weight loss for obese adults. Intensive counseling involves more than one session per month for at least 3 months.
Clinical Consideration: www.ahrq.gov/clinic/uspstf/uspsobes.htm
Clinical Consideration: www.ahrq.gov/clinic/uspstf/uspsobes.htm
Obesity
Optimal weight management in children and adolescents is desirable. The effectiveness of screening and counseling for overweight is uncertain.
Oral Cancer
The AAFP concludes that the evidence is insufficient to recommend for or against routinely screening adults for oral cancer.
Clinical Consideration: www.ahrq.gov/clinic/uspstf/uspsoral.htm
Clinical Consideration: www.ahrq.gov/clinic/uspstf/uspsoral.htm
Osteoporosis
The AAFP recommends routinely screening women aged 65 and older for osteoporosis.
Clinical Considerations:
www.ahrq.gov/clinic/3rduspstf/osteoporosis/osteorr.htm#consideration
Clinical Considerations:
www.ahrq.gov/clinic/3rduspstf/osteoporosis/osteorr.htm#consideration
Osteoporosis
The AAFP recommends routinely screening women aged 60 and older at increased risk for osteoporotic fractures.
Clinical Considerations:
www.ahrq.gov/clinic/3rduspstf/osteoporosis/osteorr.htm#consideration
Clinical Considerations:
www.ahrq.gov/clinic/3rduspstf/osteoporosis/osteorr.htm#consideration
Osteoporosis
The AAFP recommends counseling females age 11 and older to maintain adequate calcium intake prevent osteoporosis.
Clinical Considerations:
www.ahrq.gov/clinic/3rduspstf/osteoporosis/osteorr.htm#consideration
Clinical Considerations:
www.ahrq.gov/clinic/3rduspstf/osteoporosis/osteorr.htm#consideration
Ovarian Cancer
The AAFP recommends against routine screening for ovarian cancer.
Clinical Considerations: www.ahrq.gov/clinic/uspstf/uspsovar.htm
Clinical Considerations: www.ahrq.gov/clinic/uspstf/uspsovar.htm
Ovarian Cancer/BRCA Mutation Testing
The AAFP recommends that women whose family history is associated with an increased risk for deleterious mutations in BRCA1 or BRCA2 genes be referred for genetic counseling and evaluation for BRCA testing.
Clinical Consideration: www.ahrq.gov/clinic/uspstf05/brcagen/brcagenrs.htm#clinical
Clinical Consideration: www.ahrq.gov/clinic/uspstf05/brcagen/brcagenrs.htm#clinical
Ovarian Cancer/BRCA Mutation Testing
The AAFP recommends against routine referral for genetic counseling or routine breast cancer susceptibility gene (BRCA) testing for women whose family history is not associated with increased risk for deleterious mutations in breast cancer susceptibility gene 1 (BRCA1) or breast cancer susceptibility gene 2 (BRCA2).
Clinical Consideration: www.ahrq.gov/clinic/uspstf05/brcagen/brcagenrs.htm#clinical
